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Abstract
The pathophysiology of tobacco-related diseases is complex
and multifactorial. Among the various compounds in tobacco
smoke are carcinogens such as nitrosamines, irritants such as a
variety of phenolic compounds, volatiles such as carbon
monoxide, and of course nicotine. Nicotine itself has quite
complex actions, mediated in part by nicotinic cholinergic
receptors that may have extraneuronal, as well as neuronal
distribution. Its actions have also been implicated in a variety
of neurodegenerative and psychiatric disorders. This short
review discusses the recent pharmacology of nicotine and recent
progress on its possible therapeutic benefits.
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Introduction
There is little doubt that the majority of people who smoke
tobacco do so in order to experience the psychopharmacological
properties of nicotine present in smoke and that a significant
proportion of habitual tobacco users become addicted to the
drug.1  As a result, nicotine itself has been used increasingly by
many smokers wanting to stop smoking highlighting its
important therapeutic role. However, nicotine has also been
found to influence neural systems in the brain that are thought
to be involved in a range of neurological disorders. The rate of
smoking is much higher in schizophrenics (up to 90%),
depressed patients (up to 65%) and alcoholics (up to 90%) than
in the general population.2 It appears that these effects of
nicotine are mediated through selective activation of different
subtypes of the neuronal nicotinic acetylcholine receptor
(nAChR). Nicotine interacts with a variety of pre-synaptic
nAChRs to facilitate the release of a number of
neurotransmitters including acetylcholine (ACh), dopamine
(DA), noradrenaline (NA), serotonin (5-HT), gamma-
aminobutyric acid (GABA) and glutamate, many of which play
an important role in mediating a number of cognitive functions.3
Recent studies on the effects of nicotinic receptor stimulation
in neural dysfunction show the potential for therapeutic utility
of nicotinic drugs.
Neuronal nicotinic receptors
Nicotinic receptors are cationic channels mediating fast
synaptic transmission whose opening is controlled by ACh and
nicotinic receptor agonists such as nicotine.4,5 They belong to a
large family of homologous receptors including GABA
A
, glycine
and the 5-HT
3
 receptor.6 A number of different subtypes exist
with individual pharmacological and physiological profiles and
distinct anatomical distribution in the brain.7 To date, eight
alpha (alpha2-7, 9, 10) and three beta (beta2 – beta4) nAChR
subunits have been identified in mammals.8 By analogy with
the muscle nAChRs, neuronal nAChRs are believed to have a
pentameric structure consisting of five membrane spanning
regions around a central ion channel. Although much is known
about the structure and functional properties of neuronal
nAChRs, relatively little is understood about their physiological
role in man.9 Evidence suggests that nAChRs do not appear to
function solely in the classical postsynaptic manner as their
muscle counterparts as their location in the brain is not limited
to postsynaptic but also to pre-, peri- and extrasynaptic sites
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where they can modulate neuronal function by a variety of
actions.10 These include a number of functional processes such
as learning and memory, attention, cerebral blood flow and
metabolism, as well as a growing list of pathological disorders11,12
including Alzheimer’s disease (AD) in which there is a significant
loss of nAChR sites.13
Nicotine withdrawal and reinforcement
Withdrawal from nicotine following smoking cessation
results in symptoms such as depression, frustration, agitation,
anxiety, difficulty of concentration and craving for tobacco.
Although nicotine replacement therapies (NRTs) have been well
established as smoking cessation aids following their ability to
reverse the effects of nicotine withdrawal14,15 , some
antidepressants such as fluoxetine and buproprion have also
been reported to have beneficial effects on nicotine withdrawal
symptoms.16 Moreover, buproprion appears to work equally well
in smokers with and without past history of depression,
suggesting that the efficacy of the drug is not due to its
antidepressant effect. In behavioural studies using animal
models, cessation of continuous nicotine infusions produces
withdrawal symptoms similar to opiate withdrawal suggesting
a possible common physiological mechanism.17
Several behavioural studies have demonstrated the
reinforcing properties of nicotine in animal models, which are
also quite evident in humans. Nicotine can maintain self-
administration behaviour in rats, and lesion and discrete
microinjection studies have demonstrated a critical role for the
mesolimbic DA pathways in nicotine self-administration.
Mutant mice lacking the beta2 nAChR subunit do not self-
administer nicotine denoting the possible involvement of
functional beta2-containing nAChR subtypes in the rewarding
effects of nicotine.18
Nicotine and Parkinson’s disease
Parkinson’s disease (PD) is a progressive neurodegenerative
condition involving the dopaminergic neurons of the substantia
nigra. It is characterised by difficulty in initiating and smoothly
sustaining movement. In PD there is loss of cholinergic cells in
the basal forebrain accompanied by a significant reduction in
the number of nicotine binding sites in the brain.9 The etiology
of the disease is unknown, although it appears to be
multifactorial in origin, possibly arising from a complex
interaction between genetics and environment.19 The most
commonly used treatment is dopamine replacement therapy.
Although initially very effective, L-dopa provides only
symptomatic relief with an inevitable disease progression.
Moreover it loses efficacy with time and is accompanied by the
development of drug-induced side effects.20
The rationale for considering nicotine as a possible
therapeutic agent is based on epidemiological findings that PD
is less prevalent in smokers. Indeed this is the most robust
observation linking environment and PD.21 Although cigarette
smoking is composed of thousands of chemicals, nicotine
represents a possible candidate for two reasons: it stimulates
dopaminergic neurons that are selectively damaged in the
striatum of PD patients and its exposure has been reported to
protect against insults in various experimental models. Indeed,
the inverse association between smoking and PD has been
consistently reported in over 40 independent studies by different
investigators over the past 50 years.19 Furthermore, the effects
of smoking are dose dependent and related to the number of
cigarette-pack-years.22 Although many questions remain
unanswered, a recent study in twins demonstrating a reduced
PD risk with smoking led the authors to conclude that there is a
protective effect of cigarette smoking.23
Nicotine and Alzheimer’s disease
Cholinergic transmitter replacement therapy forms the
mainstay of Alzheimer’s disease (AD) symptomatic treatment
and it is based on the hypothesis that low levels of ACh are
responsible for the cognitive decline associated with the disease.
Classically, replacement therapy has involved the use of
cholinesterase inhibitors which prevent the breakdown of ACh
at the cholinergic terminals, therefore increasing the
concentration of the neurotransmitter available to interact with
the receptors. It is also likely that the therapeutic benefit of
cholinesterase inhibitor treatment occurs at least in part,
through the activation of neuronal nAChRs either by direct
action of the increased levels of ACh on these receptors or
through allosteric modulation of the receptors.9 Neuronal
nAChR activation is therefore currently being investigated as a
strategy for AD therapy. The potential therapeutic benefit in
AD from nAChR stimulation is based on three main
observations. Firstly, stimulation of nAChR by nicotine or
similar agonists improves memory function in animal models.
Secondly, nAChR activation modulates the release of a number
of neurotransmitters such as ACh, DA, GABA and glutamate
which will enhance the release of ACh. Thirdly, there is evidence
to suggest that nicotine provides protection against neurotoxic
plaque formation,24 the concentrations of which are elevated in
AD. Taking these observations, together with the reported loss
of nAChR concentrations in AD, the development of nicotine-
based therapies as potential therapeutic agents in AD should
be promising. Indeed, clinical studies using nicotine dermal
patches have reported a modest enhancement of cognitive
performance in AD patients.25,26
Nicotine and psychiatric disorders
Schizophrenia
Schizophrenia is a chronically deteriorating heterogeneous
psychosis beginning in late adolescence or early adulthood and
is characterised by hallucinations, delusions, bizarre behaviour,
apathy and blunted affect.27 Previous epidemiological studies
have shown that there is a high percentage of smokers present
in the schizophrenic population (80 - 90%) compared with the
general population (25 – 30%) and a low rate of smoking
cessation among individuals with schizophrenia.28,29
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Schizophrenic patients have also been observed to have high
levels of nAChR antibodies, which may be a contributing factor
in the reduced number of nAChRs observed in schizophrenia.
Smoking also decreases neuroleptic hepatic metabolism30
resulting in smokers needing a higher dose of antipsychotic
therapy. While it is possible that smoking causes or exacerbates
the condition, most studies suggest that the high incidence of
smoking in schizophrenic patients is an attempt on their part
to self-medicate nicotine to overcome a deficit in nicotinic
neurotransmission.1 On a receptor level, post-mortem studies
have shown a reduction in the number of alpha7-containing
nAChRs in the hippocampus of schizophrenic patients
compared to controls. Although further studies are needed to
determine the neurophysiological mechanisms involved, these
observations suggest that stimulation of this particular subunit
by nicotinic agonists, such as nicotine, may be beneficial in
schizophrenia.
Anxiety and depression
nAChRs are apparently involved in the pathophysiology of
both anxiety disorders and depression. Nicotine administration
has been observed to have anxiolytic effects in humans and in
animal models of anxiety.31,32 This action may be blocked by
antagonists to the nAChRs and by the benzodiazepine (BZ)
channel blocker flumazenil suggesting that the anxiolytic action
of nicotine may be the result of enhanced release of the
inhibitory neurotransmitter GABA, which then acts on the
central GABA
A
-BZ multi-receptor complex.
Both retrospective and prospective clinical studies have
demonstrated a relationship between smoking and major
depression. The rate of smoking is much higher in depressed
patients than in the general population.2 These patients have
greater difficulty in stopping smoking and are at an increased
risk of suffering mild to severe depression upon smoking
cessation. Epidemiological studies have shown that the
prevalence of depression in smokers is directly correlated with
the prevalence of nicotine dependence,33,34 and smokers with a
history of major depression are less likely to quit smoking.34,35
Moreover, smoking cessation frequently precipitates depressive
symptoms that can be reversed by the reintroduction of
smoking36 and evidence from clinical studies suggests that
nicotine patches have antidepressant action.37,38  Therefore, it
may appear that smoking is a self-medication effort intended
to alleviate some symptoms of depression using nicotine.
However, it is difficult to evaluate the antidepressant properties
of nicotine in smokers because it is difficult to separate the
antidepressant effect per se from the alleviation of depression
that follows nicotine withdrawal.39  There is also a considerable
body of evidence linking the action of classical tricyclic
antidepressants (TCAs) and the selective serotonin reuptake
inhibitors (SSRIs) to nAChRs. The majority of TCAs, including
imipramine, amytriptyline and nortriptyline, all produce a non-
competitive inhibition of nAChRs.40 The SSRIs fluoxetine,
paroxetine, sertaline and venlafaxine also produce similar
reversible non-competitive inhibition of nAChRs.41
Furthermore, in rat hippocampal slices, fluoxetine has been
found to inhibit nicotine-induced release of noradrenaline in a
dose-dependent manner. 42 Despite the well characterised
relationship between smoking, depression, antidepressants, and
nicotine, the role of nicotine-sensitive receptors in the brain as
targets for antidepressant treatment remains underappreciated.
Conclusion
Smoking has been shown to be associated with the
occurrence of many fatal diseases and is currently the single
most preventable cause of death. However, the possibility exists
that nicotine may be beneficial in the protection against a
number of diseases with relatively low frequencies. More studies
are needed to clarify the various possible biological effects of
tobacco smoking, particularly through its nicotine component
in neurodegenerative and psychiatric disorders.
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Dr Amanda Bartolo was this year’s winner of the
Corinthia Group Prize in Paediatrics, having obtained the
top aggregate mark over the combined examinations in
Paediatrics in the fourth and final year of the undergraduate
course. As always, competition for the Corinthia Group Prize
was as stiff as ever, with several candidates vying for the
honour.  Whilst offering our congratulations to Dr Bartolo,
we would also like to congratulate all those undergraduates
(now doctors) who performed admirably during the
undergraduate course in Paediatrics. In the accompanying
photograph, Dr Bartolo is seen receiving a cheque for Lm100
from Dr Simon Attard Montalto, Head of Paediatrics at the
Medical School. Finally, we are extremely grateful to the
Corinthia Group for their ongoing support toward the
Academic Department of Paediatrics.
Corinthia Group Prize in Paediatrics, 2005
